(E)-3-(6-氧代-3-苯基-1,6-二氢-哒嗪-4-基)-丙烯酸甲酯 | 1001620-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: (E)-3-(6-氧代-3-苯基-1,6-二氢-哒嗪-4-基)-丙烯酸甲酯
• 英文名称: methyl (E)-3-(6-oxo-3-phenyl-1H-pyridazin-4-yl)prop-2-enoate
• CAS: 1001620-03-6
• 化学式: C₁₄H₁₂N₂O₃
• 分子量: 256.261
• InChiKey: ILFPKOPEGSNDKP-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-3-(6-氧代-3-苯基-1,6-二氢-哒嗪-4-基)-丙烯酸甲酯 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以57%的产率得到(E)-3-(6-oxo-3-phenyl-1H-pyridazin-4-yl)prop-2-enoic acid
  参考文献：
  名称：

  Design, Synthesis, and Structure–Activity Relationships of a Novel Series of 5-Alkylidenepyridazin-3(2H)-ones with a Non-cAMP-Based Antiplatelet Activity

  摘要：

  5-Alkylidenepyridazin-3-ones with four points of diversity (R-2, R-6, X, Y) have been synthesized and evaluated as platelet aggregation inhibitors. Several derivatives eliciting antiplatelet activity in the low micromolar range (e.g., 14e, 14k, 14p, 14v, IC50 congruent to 1 mu M) were identified. Structure-activity relationships studies on these compounds revealed the key molecular determinants of this new family of antiplatelet agents: (a) two ester groups in the alkoxy moieties; (b) lipophilic substituents at the N2 position of the pyridazin-3-one. The preliminary results of a pharmacological study aimed at determining the mechanism of action of a set of representative compounds revealed that, unlike other pyridazinones, the documented antiplatelet effect is not a consequence of a PDE-III inhibitory activity.

  DOI：

  10.1021/jm061401d
• 作为产物：
  描述：

  5-溴-6-苯基-3(2H)-吡嗪酮 在 二氯双(三邻甲苯膦)合钯(II) 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 (E)-3-(6-氧代-3-苯基-1,6-二氢-哒嗪-4-基)-丙烯酸甲酯
  参考文献：
  名称：

  Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones

  摘要：

  A convenient and efficient palladium-catalysed retro-ene-assisted method has been developed to prepare a series of 5-substituted-6-phenyl-3(2H)-pyridazinones as potential antiplatelet drugs. The most active compounds were those that contain a 3-phenyl-3-oxo-propenyl fragment or a phenylthio group at position 5 of the heterocyclic ring. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.009

文献信息

• Pyridazine derivatives. Part 38: Efficient Heck alkenylation at position 5 of the 6-phenyl-3(2H)-pyridazinone system
  作者：Alberto Coelho、Eddy Sotelo、Héctor Novoa、Oswald M. Peeters、Norbert Blaton、Enrique Raviña

  DOI：10.1016/j.tetlet.2004.03.005

  日期：2004.4

  Several 6-phenyl-3(2H)-pyridazinones bearing different alkenyl groups at position 5 have been prepared in the search for novel antiplatelet agents. The target compounds were synthesised by a palladium-catalysed Heck cross-coupling reaction. Variable amounts of 4-phenyl-6-substituted-2-phthalazinones were isolated as by-products during these experiments. The crucial issues for successful Heck coupling

  为了寻找新型抗血小板剂，已经制备了几种在5位带有不同烯基的6-苯基-3（2 H）-哒嗪酮。通过钯催化的Heck交叉偶联反应合成目标化合物。在这些实验中，分离出了可变数量的4-苯基-6-取代的2-邻苯二氮酮副产物。在这些系统中成功进行Heck偶联的关键问题涉及杂环的位置2的保护以及使用三（邻甲苯基）膦作为配体。
• Pyridazine Compounds, Compositions and Methods
  申请人：Watterson Martin

  公开号：US20080318899A1

  公开（公告）日：2008-12-25

  The invention relates to novel chemical compounds and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

  本发明涉及新型化合物和制备和使用它们的方法。具体而言，本发明提供吡嗪化合物和/或相关的杂环衍生物，包括这些化合物的组合物，以及使用吡嗪化合物和/或相关的杂环衍生物和组合物的方法，用于调节细胞通路（例如信号转导通路），用于治疗或预防炎症性疾病（例如阿尔茨海默病），用于研究、药物筛选和治疗应用。
• PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS
  申请人：Watterson D. Martin

  公开号：US20120245125A1

  公开（公告）日：2012-09-27

  The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for, research, drug screening, and therapeutic applications.

  本发明涉及新型化合物、组合物及其制备和使用的方法。特别是，本发明提供了吡嗪化合物和/或相关的杂环衍生物，包括这些化合物的组合物，以及制备和使用这些吡嗪化合物和/或相关的杂环衍生物和组合物的方法，用于调节细胞通路（例如信号转导通路），用于治疗或预防炎症性疾病（例如阿尔茨海默病），用于研究、药物筛选和治疗应用。
• COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS
  申请人：WATTERSON D. Martin

  公开号：US20120157410A1

  公开（公告）日：2012-06-21

  The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

  本发明涉及含有吡啶二氮化合物和胆碱酯酶抑制剂的组合物、共轭物和方法，用于调节细胞途径（例如，信号转导途径），用于治疗或预防炎症性疾病（例如，阿尔茨海默病），用于研究、药物筛选和治疗应用。
• Pyridazine compounds for the treatment of inflammatory diseases
  申请人：Northwestern University

  公开号：EP2592075A1

  公开（公告）日：2013-05-15

  The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. Compounds of Formula Ia or Ib or wherein R is a substituted amino group, R2 is an unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, R3, R4, R5, and R6 are hydrogen, and R7 is absent; or a pharmaceutically acceptable salt thereof.

  本发明涉及新型化合物、组合物及其制造和使用方法。特别是，本发明提供了哒嗪化合物和/或相关杂环衍生物、包含这些化合物的组合物，以及制造和使用哒嗪化合物和/或相关杂环衍生物及包含这些化合物的组合物的方法，用于调节细胞通路（如信号转导通路）、治疗或预防炎症性疾病（如阿尔茨海默氏症）、研究、药物筛选和治疗应用。 式 Ia 或 Ib 的化合物 或 其中 R 是取代的氨基，R2 是含有 1 至 4 个氮原子的不饱和 5 至 6 元杂环基团，R3、R4、R5 和 R6 是氢，R7 不存在；或其药学上可接受的盐。